Understanding therapeutic targets in thrombotic thrombocytopenic purpura

Bérangère S Joly; Karen Vanhoorelbeke; Agnès Veyradier

doi:10.1007/s00134-016-4662-3

Understanding therapeutic targets in thrombotic thrombocytopenic purpura

Intensive Care Med. 2017 Sep;43(9):1398-1400. doi: 10.1007/s00134-016-4662-3. Epub 2017 Jan 23.

Authors

Bérangère S Joly¹, Karen Vanhoorelbeke², Agnès Veyradier³

Affiliations

¹ Service d'hématologie biologique and EA3518-Institut universitaire d'hématologie, Groupe Hospitalier Saint Louis-Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, 2 rue Ambroise Paré, 75010, Paris, France.
² Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium.
³ Service d'hématologie biologique and EA3518-Institut universitaire d'hématologie, Groupe Hospitalier Saint Louis-Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, 2 rue Ambroise Paré, 75010, Paris, France. agnes.veyradier@aphp.fr.

PMID: 28116452
DOI: 10.1007/s00134-016-4662-3

No abstract available

Keywords: ADAMTS13 Deficiency; Eculizumab; High Molecular Weight Multimers; Thrombotic Thrombocytopenic Purpura; Thrombotic Thrombocytopenic Purpura Patient.

MeSH terms

ADAMTS13 Protein / deficiency
ADAMTS13 Protein / immunology
ADAMTS13 Protein / therapeutic use
Autoantibodies* / blood
Autoantibodies* / drug effects
Autoantibodies* / immunology
Clinical Trials as Topic
Critical Care / methods
Humans
Immunologic Factors / therapeutic use*
Intensive Care Units
Plasma Exchange*
Purpura, Thrombotic Thrombocytopenic* / blood
Purpura, Thrombotic Thrombocytopenic* / immunology
Purpura, Thrombotic Thrombocytopenic* / mortality
Purpura, Thrombotic Thrombocytopenic* / therapy
Recurrence

Substances

Autoantibodies
Immunologic Factors
ADAMTS13 Protein